Scott Wadler

Scott Wadler

UNVERIFIED PROFILE

Are you Scott Wadler?   Register this Author

Register author
Scott Wadler

Scott Wadler

Publications by authors named "Scott Wadler"

Are you Scott Wadler?   Register this Author

39Publications

280Reads

23Profile Views

A phase I study of the chinese herbal medicine PHY906 as a modulator of irinotecan-based chemotherapy in patients with advanced colorectal cancer.

Clin Colorectal Cancer 2011 Jun 22;10(2):85-96. Epub 2011 Apr 22.

Department of Medicine and Pharmacology, Developmental Therapeutics Program, Yale Cancer Center, Yale University School of Medicine, New Haven, CT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clcc.2011.03.003DOI Listing
June 2011

Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III.

Gynecol Oncol 2007 Sep 22;106(3):453-60. Epub 2007 Jun 22.

Albert Einstein College of Medicine, and Albert Einstein Cancer Center, Bronx, NY 10461, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2007.04.038DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2013935PMC
September 2007

Targeted therapy in colorectal cancer.

Authors:
Scott Wadler

Clin Colorectal Cancer 2007 Jan;6(5):357-61

Weill Medical College of Cornell University, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CCC.2007.n.004DOI Listing
January 2007

Molecular targeting in pancreatic cancer.

Authors:
Scott Wadler

Rev Recent Clin Trials 2007 Jan;2(1):69-75

Richard T. Silver Distinguished Professor of Hematology and Medical Oncology, Weill Medical College of Cornell University, 1300 York Avenue, New York, 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/157488707779318152DOI Listing
January 2007

Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer: an NYGOG and ECOG study.

Gynecol Oncol 2006 Feb 25;100(2):324-9. Epub 2005 Oct 25.

NYU School of Medicine and Cancer Institute, 160 East 34th Street, New York, NY 10016, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2005.08.059DOI Listing
February 2006

Phase II trial of thalidomide for advanced and recurrent gynecologic sarcoma: a brief communication from the New York Phase II consortium.

Gynecol Oncol 2006 Jan 29;100(1):160-5. Epub 2005 Sep 29.

Division of Gynecologic Oncology, Department of Obstetrics/Gynecology, Weill Medical College of Cornell University, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S009082580500707
Publisher Site
http://dx.doi.org/10.1016/j.ygyno.2005.08.033DOI Listing
January 2006

A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas.

Cancer 2005 Apr;103(7):1431-8

Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021-6007, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.20968DOI Listing
April 2005

Thalidomide for advanced hepatocellular carcinoma: is this a real alternative?

Authors:
Scott Wadler

Cancer 2005 Jan;103(1):1-4

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.20731DOI Listing
January 2005

Recommended guidelines for the treatment of cancer treatment-induced diarrhea.

J Clin Oncol 2004 Jul;22(14):2918-26

Robert H. Lurie Comprehensive Cancer Center of Northwestern University, 676 N St Clair, Suite 850, Chicago, IL 60611, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2004.04.132DOI Listing
July 2004

Decreased short- and long-term swallowing problems with altered radiotherapy dosing used in an organ-sparing protocol for advanced pharyngeal carcinoma.

Arch Otolaryngol Head Neck Surg 2004 Jul;130(7):831-6

Department of Otolaryngology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10467, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/archotol.130.7.831DOI Listing
July 2004

Phase II clinical trial of parenteral hydroxyurea in combination with fluorouracil, interferon and filgrastim in the treatment of advanced pancreatic, gastric and neuroendocrine tumors.

Cancer Chemother Pharmacol 2004 Apr 24;53(4):337-40. Epub 2003 Dec 24.

Department of Medicine, Albert Einstein College of Medicine and the Albert Einstein Comprehensive Cancer Center, Bronx, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-003-0727-4DOI Listing
April 2004

Topotecan is an active agent in the first-line treatment of metastatic or recurrent endometrial carcinoma: Eastern Cooperative Oncology Group Study E3E93.

J Clin Oncol 2003 Jun;21(11):2110-4

Department of Oncology, Division of Hematology-Oncology, Weill Medical College of Cornell University, 525 E 68th St, STARR 353, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2003.12.093DOI Listing
June 2003

Clinical applications of p53-directed gene therapy.

Suppl Tumori 2002 Nov-Dec;1(6):S21

Weill Medical College of Cornell University, New York, NY, USA.

View Article

Download full-text PDF

Source
April 2003

Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer.

J Clin Oncol 2003 Apr;21(8):1498-504

Pfizer Global Research and Development, 2800 Plymouth Rd, Ann Arbor, MI 48105, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2003.09.114DOI Listing
April 2003

A pilot study of edrecolomab (Panorex, 17-1A antibody) and capecitabine in patients with advanced or metastatic adenocarcinoma.

Cancer Invest 2003 Apr;21(2):177-84

Department of Oncology, Montefiore Medical Center/Albert Einstein Cancer Center, 111 E 210 Street, Bronx, NY 10467, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1081/cnv-120016413DOI Listing
April 2003

Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies.

Clin Cancer Res 2003 Feb;9(2):693-702

Division of Hematology/Oncology, Department of Medicine, Weill Medical College of Cornell University, New York, New York 10021, USA.

View Article

Download full-text PDF

Source
February 2003

A phase II study of rebeccamycin analog NSC 655649 in patients with metastatic colorectal cancer.

Invest New Drugs 2003 Feb;21(1):103-7

Department of Oncology, Montefiore Medical Center, Bronx, NY 10461, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1023/a:1022980613420DOI Listing
February 2003

Persistent replication of the modified chimeric adenovirus ONYX-015 in both tumor and stromal cells from a patient with gall bladder carcinoma implants.

Clin Cancer Res 2003 Jan;9(1):33-43

Department of Medicine, Weill Medical College of Cornell University, New York, New York 10021, USA.

View Article

Download full-text PDF

Source
January 2003

Randomized phase II trial of embolization therapy versus chemoembolization therapy in previously treated patients with colorectal carcinoma metastatic to the liver.

Clin Colorectal Cancer 2002 Nov;2(3):173-9

Department of Radiology, Albert Einstein College of Medicine and the Albert Einstein Comprehensive Cancer Center, Bronx, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CCC.2002.n.022DOI Listing
November 2002

SU9516, a cyclin-dependent kinase 2 inhibitor, promotes accumulation of high molecular weight E2F complexes in human colon carcinoma cells.

Biochem Pharmacol 2002 Oct;64(7):1091-100

Albert Einstein Comprehensive Cancer Center and the Albert Einstein College of Medicine, Bronx, NY 10463, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0006-2952(02)01264-9DOI Listing
October 2002

Phase I clinical trial of irinotecan with oral capecitabine in patients with gastrointestinal and other solid malignancies.

Am J Clin Oncol 2002 Oct;25(5):528-34

Department of Hematology/Oncology, Montefiore Medical Center/Albert Einstein College of Medicine and Albert Einstein Comprehensive Cancer Center Bronx, NY 10461, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/00000421-200210000-00022DOI Listing
October 2002

Phase I and pharmacologic study of i.p. 9-aminocamptothecin given as six fractions over 14 days.

Anticancer Drugs 2002 Sep;13(8):819-25

NYU Cancer Institute, Division of Medical Oncology, New York University School of Medicine, New York, NY 10016, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/00001813-200209000-00006DOI Listing
September 2002

Radiofrequency ablation of head and neck tumors: dramatic results from application of a new technology.

Head Neck 2002 Aug;24(8):754-8

Department of Surgery, Head and Neck Division, Montefiore Medical Center of the Einstein College of Medicine, 111 E 210th Street, Bronx, NY 10467, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hed.10119DOI Listing
August 2002

Phase I clinical trial of parenteral hydroxyurea in combination with pelvic and para-aortic external radiation and brachytherapy for patients with advanced squamous cell cancer of the uterine cervix.

Int J Radiat Oncol Biol Phys 2002 Mar;52(3):637-42

Department of Radiation Oncology, Montefiore Medical Center, Albert Einstein College of Medicine and Albert Einstein Cancer Center, Bronx, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0360-3016(01)02662-1DOI Listing
March 2002